Honored and grateful to be among the 2026 Conquer Cancer Grants & Awards recipients. Thank you, @ConquerCancerFd and @ASCO for investing in the next generation of oncology researchers and leaders. Looking forward to #ASCO26 in Chicago! 🎗️🌍 #ResearchConquersCancer #ConquerCancer #ASCO26 #CancerResearch #Oncology #GlobalOncology #CancerCare #FutureOfOncology

🎉 Our new study is now published in JCO Global Oncology! 💊🖐️ Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study 🔬 In this prospective, two-center real-world study of 151 patients receiving capecitabine-based therapy, we evaluated prophylactic topical diclofenac for the prevention of clinically significant hand-foot syndrome (HFS). 📊 Grade ≥2 HFS occurred in 16.9% (12/71) with topical diclofenac versus 13.8% (11/80) with active monitoring (OR 1.28; 95% CI, 0.52–3.10; P = .591). 💡 Our findings showed that prophylactic topical diclofenac did not reduce clinically significant HFS or delay its onset in routine clinical practice, adding prospective real-world evidence to this evolving area of supportive oncology. 🙏 Special thanks to our first author, Dr. Orhun Akdoğan(@drOrhunakdogan) and our mentor, Dr. Osman Sütcüoğlu(@osutcuoglu) for their leadership and guidance, and to our entire team(@uyargalip, @kbaskurtt, @yucelbirkadriye) for their valuable contributions. Grateful to be part of this collaboration! 📖 @JCOGO_ASCO | @ASCO 🔗 ascopubs.org/doi/pdf/10.1200… #JCOGlobalOncology #ASCO #Oncology #SupportiveCare #Capecitabine #HandFootSyndrome #RealWorldEvidence @KVanLoonMD @RyanNipp @thenasheffect @IshwariaMD @ASCOPres

📄 Our paper, developed from my internal medicine residency thesis at Akdeniz University (@Akdenizun), is now published in @Cancers_MDPI . 🧠 We studied 166 patients with recurrent glioblastoma, IDH-wildtype. At first recurrence, 114 received a bevacizumab-containing strategy and 52 a non-bevacizumab strategy. 🔎 After propensity-score overlap weighting with multiple imputation, bevacizumab-containing treatment was not associated with improved post-recurrence overall survival (HR 1.40, 95% CI 0.93 to 2.10) or prPFS (HR 0.81, 95% CI 0.55 to 1.18). ⚠️ Yet documented second progression was much less frequent with bevacizumab (cause-specific HR 0.29, 95% CI 0.16 to 0.53), while death before documented progression was more frequent (HR 1.65, 95% CI 0.93 to 2.93). At 24 months, documented second progression was 20.2% vs 55.3%, while death before documented progression was 65.5% vs 34.7%. ⚖️ This is important because prPFS combines events moving in opposite directions. In the antiangiogenic setting, less radiographic progression does not necessarily translate into better disease control or longer survival. 🙏 Grateful to Prof. Dr. Sema Sezgin Göksu, Dr. Galip Can Uyar (@uyargalip), and my mentor Assoc. Prof. Dr. Osman Sütcüoğlu ( @osutcuoglu) for their support throughout this project. 🔗 mdpi.com/2072-6694/18/16/266… @EANOassociation #Glioblastoma #NeuroOncology #MedicalOncology #Bevacizumab #CancerResearch #EANO

🇨🇭 Two inspiring days at the @myESMO Preceptorship on Endometrial Cancer in Lugano. 🎤 Honored to present our challenging case on dostarlimab-associated bowel perforation in MSI-H, p53-mutant endometrial cancer and discuss it with leading experts. 🌸 One unforgettable moment: while describing my patient’s remarkable recovery, I said, “the patient became like a flower.” The room burst into laughter only to realize that many colleagues across Europe use the very same expression. 🙏 My sincere thanks to @Ilaria_Colombo_, Fabian Trillsch, Nicoletta Colombo, Nicole Concin, @PrJEKurtz, Domenica Lorusso, Frederik Marmé, @xmatiasguiu, and Alina Sturdza for their inspiring lectures, insightful discussions, and valuable feedback. 🇹🇷 Proud to represent Türkiye. #ESMO #EndometrialCancer #GynecologicOncology #MedicalOncology #Oncology #Lugano